Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064515 · ClinicalTrials.gov registry record
CTCs in Cervix Cancer
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 4
- Enrollment target
NCT04064515: Completed study, sponsored by NYU Langone Health.
NCT04064515 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04064515 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.
Interventions
- DIAGNOSTIC_TEST Blood Assayed for CTCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2020-04-23 |
What the finished NCT04064515 record still lists
NCT04064515 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Assayed for CTCs is the first listed.
NCT04064515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04064515 about?
NCT04064515 is a clinical study titled "CTCs in Cervix Cancer". This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.
What is the current status of trial NCT04064515?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2020-03-02. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT04064515?
The interventions under investigation include: Blood Assayed for CTCs (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04064515?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI